Literature DB >> 22901799

Contraception for men: a breakthrough new approach.

William J Bremner1.   

Abstract

There has not been a new reversible contraceptive for men since the development of the condom, centuries ago. Matzuk et al. describe a new molecular approach using administration of a small molecule to directly and reversibly inhibit spermatogenesis in mice by blocking the function of a testicular bromodomain without apparent adverse effect on the organism or offspring.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22901799      PMCID： PMC4388035          DOI： 10.1016/j.cell.2012.07.027

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  8 in total

1.  Trends in contraceptive use in the United States: 1982-1995.

Authors:  L J Piccinino; W D Mosher
Journal:  Fam Plann Perspect       Date:  1998 Jan-Feb

2.  Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis.

Authors:  John K Amory; Charles H Muller; Jakob A Shimshoni; Nina Isoherranen; Jisun Paik; Jan S Moreb; David W Amory; Ryan Evanoff; Alex S Goldstein; Michael D Griswold
Journal:  J Androl       Date:  2010-08-12

3.  Oral administration of a retinoic Acid receptor antagonist reversibly inhibits spermatogenesis in mice.

Authors:  Sanny S W Chung; Xiangyuan Wang; Shelby S Roberts; Stephen M Griffey; Peter R Reczek; Debra J Wolgemuth
Journal:  Endocrinology       Date:  2011-04-19       Impact factor: 4.736

4.  The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background.

Authors:  Binyamin D Berkovits; Debra J Wolgemuth
Journal:  Dev Biol       Date:  2011-10-12       Impact factor: 3.582

5.  The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation.

Authors:  Enyuan Shang; Helen D Nickerson; Duancheng Wen; Xiangyuan Wang; Debra J Wolgemuth
Journal:  Development       Date:  2007-08-29       Impact factor: 6.868

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

7.  Small-molecule inhibition of BRDT for male contraception.

Authors:  Martin M Matzuk; Michael R McKeown; Panagis Filippakopoulos; Qinglei Li; Lang Ma; Julio E Agno; Madeleine E Lemieux; Sarah Picaud; Richard N Yu; Jun Qi; Stefan Knapp; James E Bradner
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

8.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962
  8 in total
  1 in total

Review 1.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.